Hot

Anti-human CD56 Antibody (N901, Mouse IgG2a Kappa)

Anti-human CD56 Antibody (N901, Mouse IgG2a Kappa) PA007347.m2a Syd Labs | Ushelf

Anti-human CD56 Antibody (N901, Mouse IgG2a Kappa)

$60.00 – $120.00

In stock
Catalog No.: PA007347.m2a | Isotype: Mouse IgG2a Kappa | Flow Cytometry

$60.00 – $120.00

Recombinant mouse anti-human CD56 monoclonal antibody (Clone N901), expressed in mammalian cells. Variable regions are derived from anti-human CD56 clone N901 and expressed with a Mouse IgG2a heavy chain, providing high specificity for the phenotypic identification and functional analysis of human natural killer (NK) cells and NKT cell subsets.

  • Host & Isotype: Mouse IgG2a, kappa (Recombinant)
  • Applications: Flow Cytometry (FC), Cell Isolation, Functional Assays
  • Alternative Formats: Other recombinant isotype and conjugated formats of clone N901 are also available at Syd Labs and Ushelf.
Clear
View cart
Order Offline:
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Catalog No. PA007347.m2a
Product Name Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901), Mouse IgG2a Kappa
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Clone N901.
Isotype Mouse IgG2a kappa.
Source/Host The recombinant anti-human CD56 monoclonal antibody (clone: N901) was produced in mammalian cells.
Specificity/Sensitivity The recombinant mouse monoclonal antibody (clone: N901) specifically binds to the human CD56 protein.
Applications Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form Of Antibody 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Conjugate Non-conjugated.
Purity >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping The N901 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note

Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007347.m2a: Non-conjugated Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901), Mouse IgG2a Kappa

Recombinant Mouse IgG2a Monoclonal Antibody.

The recombinant N901 antibody binds to the human CD56 protein, a homophilic binding glycoprotein expressed on the surface of neurons, glia and skeletal muscle. CD56 is a marker of neural lineage commitment. CD56 expression is found in the hematopoietic system, natural killer cells, and other lymphoid cells, including gamma delta (??) T cells and activated CD8+ T cells, as well as on dendritic cells. CD56 has a role in cell?cell adhesion, neurite outgrowth, synaptic plasticity, and learning and memory.

References of Anti-Human CD56 Monoclonal Antibody (Clone: N901):

1. Reduced Immunosenescence of Peripheral Blood T Cells in Parkinson’s Disease with CMV Infection Background

Kustova, S. A., et al. Biomedicines. 2021 Dec 2;9(12):1819. PMID: 34944635

“Immunosenescence is a process of remodeling the immune system under the influence of chronic inflammation during aging. Parkinson’s disease (PD) is a common age-associated neurodegenerative disorder and is frequently accompanied by neuroinflammation. Thus, PD is characterized by reduced peripheral blood T cell immunosenescence, even against the background of CMV infection.”

2. Surface NKG2C Identifies Differentiated γδT-Cell Clones Expanded in Peripheral Blood

Kovalenko, E. I., et al. Front Immunol. 2021 Feb 16;11:613882. PMID: 33664730

“T cells that express CD56 in peripheral blood of healthy humans represent a heterogeneous and poorly studied subset. In both CD56+ and CD56- subsets most of the NKG2C+ T cells had a phenotype of highly differentiated CD8+ TEMRA cells. Thus, NKG2C expression in highly differentiated CD56+ T cells was associated with the most expanded γδ T cell clones.”

3. Alterations in the CD56− and CD56+ T Cell Subsets during COVID-19

Kustova, S. A., et al. Int J Mol Sci. 2023 May 16;24(10):9047. PMID: 37240393

“This work aimed to analyze the activation and differentiation of both circulating NKT-like cells and CD56− T cells during COVID-19 among intensive care unit (ICU) patients, moderate severity (MS) patients, and convalescents. Severe COVID-19 was accompanied by a decrease in the proportion of CD8+ T cells, mainly due to the CD56− cell death, and a redistribution of the NKT-like cell subset composition with a predominance of more differentiated cytotoxic CD8+ T cells. Overall, our findings suggest an antiviral role of CD56+ T cells in COVID-19.”

4. HLA-DR Expression in Natural Killer Cells Marks Distinct Functional States, Depending on Cell Differentiation Stage

Kust, S. A., et al. Int J Mol Sci. 2024 Apr 23;25(9):4609. PMID: 38731828

“HLA-DR-positive NK cells, found in both healthy individuals and patients with different inflammatory diseases, are characterized as activated cells. In this study, we evaluated the functional features of HLA-DR-expressing NK cells at various stages of differentiation. We demonstrated that HLA-DR expression marks distinct functional states of NK cells depending on their differentiation stage.”

5. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

Ghiringhelli, F., et al. Nat Med. 2023 Aug;29(8):2080-2089. PMID: 37563240

“Although patients with microsatellite instable metastatic colorectal cancer benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and efficacy of durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy in first line. The combination of durvalumab–tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC.”

For more technical references or data sheets regarding the Anti-Human CD56 Monoclonal Antibody (Clone: N901) formats, please contact our scientific support team at message@sydlabs.com.

Syd Labs provides the following recombinant anti-human CD56 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
Biotin Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
FITC Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
APC Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
PE Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
Pacific Blue Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
PerCP Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
PE/Cy5 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
PE/Cy7 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
iFluor 488 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
iFluor 549 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
iFluor 594 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
iFluor 647 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
iFluor 700 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
APC/Cy7 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)
PerCP/Cy5.5 Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901)